VolitionRx Narrows Losses Amid Revenue Growth, R&D Cuts

Ticker: VNRX · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 93314

Sentiment: mixed

Topics: Biotechnology, Diagnostics, Financial Performance, R&D Spending, Capital Raise, Going Concern, Share Dilution

Related Tickers: VNRX

TL;DR

**VNRX is still burning cash, but the reduced R&D spend and new financing might buy them more time to prove their tech.**

AI Summary

VolitionRx Limited (VNRX) reported a net loss of $11,790,697 for the six months ended June 30, 2025, a significant improvement from the $15,532,180 net loss in the prior-year period. Total revenues increased to $653,073 for the six months ended June 30, 2025, up from $567,332 in the same period of 2024, driven by a rise in service revenue to $277,254 from $155,866. Product revenue, however, saw a slight decrease to $375,819 from $411,466. Operating expenses decreased by 21.7% to $12,472,270 from $15,942,255, primarily due to a substantial reduction in research and development expenses from $8,345,324 to $5,327,321. The company's cash and cash equivalents declined to $2,255,996 as of June 30, 2025, from $3,264,429 at December 31, 2024. Total liabilities increased to $41,803,112 from $35,507,259, largely due to new convertible note payable and derivative liabilities. The company also issued common stock for cash, generating $2,447,214 in net proceeds, and secured $5,802,799 from the issuance of convertible notes and warrants.

Why It Matters

For investors, VolitionRx's reduced net loss and increased revenue, despite a dip in product sales, signal potential operational efficiencies and a strategic shift in R&D spending. The significant increase in total liabilities, particularly the new convertible note and derivative liabilities, introduces financial complexity and potential dilution risks that warrant close scrutiny. The company's continued reliance on financing activities, including common stock issuances and convertible notes, suggests ongoing capital needs, which could impact existing shareholders. In a competitive diagnostics market, VNRX's ability to commercialize its Nucleosomics technology and achieve profitability remains a critical factor for its long-term viability and market position.

Risk Assessment

Risk Level: high — VolitionRx reported a net loss of $11,790,697 for the six months ended June 30, 2025, and its cash and cash equivalents decreased to $2,255,996 from $3,264,429. The company's total stockholders' deficit worsened to $(33,098,322) from $(26,107,736) at December 31, 2024, indicating a precarious financial position and a going concern risk.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor future filings closely for signs of sustained revenue growth, further reductions in net loss, and successful commercialization of their diagnostic products. The significant increase in liabilities and ongoing cash burn necessitate a clear path to profitability before considering a long position.

Financial Highlights

debt To Equity
N/A
revenue
$653,073
operating Margin
N/A
total Assets
$8,704,790
total Debt
$41,803,112
net Income
-$11,790,697
eps
-$0.06
gross Margin
N/A
cash Position
$2,255,996
revenue Growth
+15.1%

Revenue Breakdown

SegmentRevenueGrowth
Service Revenue$277,254+78.0%
Product Revenue$375,819-8.7%

Key Numbers

Key Players & Entities

FAQ

What were VolitionRx's total revenues for the six months ended June 30, 2025?

VolitionRx's total revenues for the six months ended June 30, 2025, were $653,073, an increase from $567,332 in the same period of 2024.

How did VolitionRx's net loss change in the first half of 2025 compared to 2024?

VolitionRx's net loss for the six months ended June 30, 2025, was $11,790,697, which is an improvement from the $15,532,180 net loss reported for the same period in 2024.

What was the primary driver for the decrease in VolitionRx's operating expenses?

The primary driver for the decrease in VolitionRx's operating expenses was a significant reduction in research and development expenses, which fell to $5,327,321 for the six months ended June 30, 2025, from $8,345,324 in the prior-year period.

What is VolitionRx's cash position as of June 30, 2025?

As of June 30, 2025, VolitionRx had cash and cash equivalents of $2,255,996, a decrease from $3,264,429 at December 31, 2024.

How much capital did VolitionRx raise from convertible notes and warrants in the first half of 2025?

VolitionRx received net proceeds of $5,802,799 from the issuance of convertible notes and warrants during the six months ended June 30, 2025.

What is the current status of VolitionRx's stockholders' deficit?

VolitionRx's total stockholders' deficit worsened to $(33,098,322) as of June 30, 2025, compared to $(26,107,736) at December 31, 2024.

What are the key risks highlighted in VolitionRx's 10-Q filing?

Key risks include the inability to generate significant revenues or achieve profitability, the need to raise additional capital, dependence on third-party distributors, and material weaknesses in internal control over financial reporting, as well as a 'going concern' opinion from auditors.

How many shares of common stock were outstanding for VolitionRx as of August 7, 2025?

As of August 7, 2025, there were 107,595,421 shares of VolitionRx's common stock issued and outstanding.

What are VolitionRx's primary product and service offerings?

VolitionRx's primary offerings revolve around its Nucleosomics technology, including trademarks like Nucleosomics, Capture-PCR, Nu.Q, and Capture-Seq, which are diagnostic technologies.

Did VolitionRx receive any grant income in the first half of 2025?

Yes, VolitionRx reported grant income of $197,227 for the six months ended June 30, 2025, compared to no grant income in the same period of 2024.

Risk Factors

Industry Context

VolitionRx operates in the diagnostics and biotechnology sector, focusing on developing and commercializing novel cancer detection tests. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Competition is intense, with established players and emerging companies vying for market share through innovation and strategic partnerships.

Regulatory Implications

As a developer of diagnostic tests, VolitionRx is subject to stringent regulatory oversight from bodies like the FDA. Obtaining regulatory approval for new tests is a critical and often lengthy process. Compliance with evolving healthcare regulations and data privacy laws is also paramount to avoid penalties and maintain market access.

What Investors Should Do

  1. Monitor cash burn rate and future financing needs.
  2. Evaluate the progress of product development and regulatory approvals.
  3. Analyze the trend in service revenue growth.
  4. Assess the impact of increased liabilities and convertible notes.

Glossary

Accumulated deficit
The total net losses of a company since its inception that have not been offset by net income. (Indicates the company's historical unprofitability and the cumulative losses incurred over time, contributing to the overall stockholders' deficit.)
Convertible note payable
A debt instrument that can be converted into a predetermined amount of the issuer's equity at the option of the holder. (Represents a form of financing that can lead to future dilution of existing shareholders' equity if converted.)
Derivative liability
A financial instrument whose value is derived from an underlying asset, index, or security, and which represents an obligation for the company. (The recognition of a new derivative liability suggests complex financial arrangements that could impact future financial performance.)
Stockholders' Deficit
The amount by which a company's liabilities exceed its total assets, resulting in a negative equity position. (A negative stockholders' deficit, as reported by VNRX, signifies that the company owes more than it owns, raising concerns about its financial health.)
Warrant liability
A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (Represents potential future dilution and a financial obligation that impacts the company's balance sheet.)

Year-Over-Year Comparison

Compared to the prior year, VolitionRx has shown a 15.1% increase in total revenues, driven by a substantial 78.0% surge in service revenue, although product revenue saw a slight 8.7% decline. The company has significantly reduced its net loss by 24%, largely due to a 36% decrease in R&D expenses. However, the financial position has weakened, with cash and cash equivalents down 31% and total liabilities increasing by 17.7%, leading to a worsened stockholders' deficit.

Filing Stats: 4,364 words · 17 min read · ~15 pages · Grade level 20 · Accepted 2025-08-14 16:54:18

Key Financial Figures

Filing Documents

FINANCIAL STATEMENTS (UNAUDITED)

FINANCIAL STATEMENTS (UNAUDITED) 4 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 37 Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 45 Item 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 45 PART II OTHER INFORMATION Item 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 47 Item 1A.

RISK FACTORS

RISK FACTORS 47 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 47 Item 3. DEFAULTS UPON SENIOR SECURITIES 48 Item 4. MINE SAFETY DISCLOSURES 48 Item 5. OTHER INFORMATION 48 Item 6. EXHIBITS 49

SIGNATURES

SIGNATURES 50 2 Table of Contents U se of Terms Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to the "Company," "VolitionRx," "Volition," "we," "us," and "our" are references to VolitionRx Limited and its wholly owned subsidiaries, Volition Global Services SRL, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., and its majority-owned subsidiary, Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. Nucleosomics TM, , Capture-PCR TM , Nu.Q and Capture-Seq TM and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to herein are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 , (this "Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which statements are subject to considerable risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. We have attempted to identify forward-looking statements by using words such as "aim," "anticipate," "believe," "continue," "could," "estimate(s)," "expect," "forecast(s)," "goal," "intend," "may," "plan(s)," "potential," "project," "seek," "should," "strategy," "will," and other forms of these words or similar

FINANCIAL STATEMENTS (UNAUDITED)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED) Page Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations and Comprehensive Loss 6 Condensed Consolidated Statements of Stockholders' Deficit 7 Condensed Consolidated Statements of Cash Flows 9 Notes to the Condensed Consolidated Financial Statements 10 4 Table of Contents VOL ITIONRX LIMITED Condensed Consolidated Balance Sheets (Expressed in United States Dollars, except share numbers) June 30, December 31, 2025 2024 $ $ ASSETS (UNAUDITED) Current Assets Cash and cash equivalents 2,255,996 3,264,429 Accounts receivable 189,597 110,574 Prepaid expenses 474,468 338,660 Other current assets 343,246 343,145 Total Current Assets 3,263,307 4,056,808 Property and equipment, net 4,500,065 4,429,152 Operating lease right-of-use assets 635,041 599,816 Intangible assets, net 306,377 313,747 Total Assets 8,704,790 9,399,523 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable 2,351,261 2,766,178 Accrued liabilities 4,389,312 3,476,903 Deferred revenue 122,441 230,000 Management and directors' fees payable 54,392 30,086 Current portion of long-term debt 1,017,348 860,223 Current portion of finance lease liabilities 53,842 46,737 Current portion of operating lease liabilities 252,013 221,755 Current portion of grant repayable 69,345 60,979 Warrant liability 140,612 97,886 Derivative liability 623,790 - Current portion of convertible note payable, net 166,522 - Total Current Liabilities 9,240,878 7,790,747 Deferred revenue, net of current portion 22,663,400 22,663,400 Long-term debt, net of current portion 5,771,375 3,952,846 Finance lease liabilities, net of current portion 346,291 328,338 Operating lease liabilities, net of current portion 417,015 410,686 Grant repayable, net of current portion 443,911 3

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing